MLPH rs2292884: Prostate Cancer Risk and Genetic Variation
The rs2292884 variant is a single nucleotide polymorphism located within the MLPH gene. It has been identified through genome-wide association studies as a susceptibility locus associated with prostate cancer risk.
What each genotype means
Baseline prostate cancer risk
This genotype represents the non-risk allele at this position in the MLPH gene. Research indicates that individuals with this genotype do not carry the specific variant associated with increased prostate cancer susceptibility in some studies. Please note that prostate cancer risk is complex and influenced by many genetic and environmental factors.
This is the most common genotype globally, carried by a significant majority of the population.
Slightly elevated risk profile
This genotype includes one copy of the G allele, which has been identified in genome-wide association studies as a potential risk variant for prostate cancer. While some research suggests this variant may influence MLPH expression or androgen-related signaling, the clinical impact is considered modest. You should discuss your overall prostate health and screening needs with your healthcare provider.
This heterozygous genotype is common, appearing in roughly 1 in 2 to 1 in 3 individuals depending on ancestral background.
Increased prostate cancer risk
This genotype consists of two copies of the G allele, which has been statistically associated with a slightly higher risk of developing prostate cancer in various population studies. The biological mechanism may involve altered MLPH gene expression or androgen receptor signaling, though the clinical significance of this specific variant remains a subject of ongoing research. It is important to maintain regular health screenings and discuss your family history and risk factors with a clinician.
This homozygous genotype is found in a substantial portion of the population, with frequencies varying across different ancestral groups.
Understanding the rs2292884 Variant
The rs2292884 variant is a specific change in the DNA sequence located within the MLPH (melanophilin) gene. In genetics, a single nucleotide polymorphism, or SNP, represents a variation at a single position in the DNA chain. Researchers identify these variants by comparing the genomes of large groups of people to see if certain genetic markers appear more frequently in individuals with a specific health condition compared to those without it. The rs2292884 variant has been studied as part of broader efforts to map the genetic architecture of prostate cancer. By pinpointing these locations, scientists can better understand the biological pathways that may contribute to disease development, though it is important to note that a single SNP typically only provides a small piece of a much larger, complex puzzle involving many genes and environmental factors.
The Role of the MLPH Gene
The MLPH gene encodes the melanophilin protein, which is primarily known for its role in intracellular vesicle transport, particularly in pigment-producing cells called melanocytes. However, research has also highlighted its potential involvement in prostate tissue. Studies suggest that MLPH may play a role in androgen-related signaling pathways, which are critical to prostate function. Some evidence indicates that the expression levels of MLPH can be influenced by genetic variants, potentially affecting how prostate cells respond to hormonal signals. While the exact mechanism remains a subject of ongoing investigation, researchers are exploring how variations in this gene might influence cellular differentiation or the behavior of prostate cells. Understanding these functions is a key step in determining how genetic differences might contribute to the susceptibility of prostate tissue to malignancy.
Research and Evidence Strength
The association between rs2292884 and prostate cancer was established through genome-wide association studies (GWAS). These large-scale studies have identified rs2292884 as a susceptibility locus, meaning individuals carrying certain alleles may show a statistically different risk profile compared to the general population. The evidence for this association is considered moderate, as the effect size of any single SNP like rs2292884 is typically small. It is not a diagnostic marker, but rather a statistical signal used in polygenic hazard models to help refine risk stratification. Because prostate cancer is a complex, multifactorial disease, this variant is just one of many genetic factors that researchers track. Current findings emphasize that while the statistical link is robust in large cohorts, the clinical utility of this information for an individual remains limited without broader context.
Population Frequency and Ancestry
The frequency of the rs2292884 variant is known to be variable across different European populations. Genetic studies often observe that the prevalence of specific alleles can shift significantly depending on the ancestral background of the study participants. This variability is a common feature of human genetic diversity and underscores the importance of conducting research across diverse groups to ensure that findings are applicable to a wide range of people. Because the variant's frequency and its associated risk can differ, researchers must account for ancestry when developing risk models. If you are reviewing genetic data, it is helpful to remember that these frequencies are based on population-level averages and do not predict the health outcomes of any specific individual.
What This Information Means for You
It is important to understand that having a specific genotype for rs2292884 does not mean you will or will not develop prostate cancer. Genetic risk scores are statistical tools used by researchers to understand population-level trends, not to provide personal medical diagnoses. If you have questions about your prostate health or your family history, the most appropriate step is to consult with a healthcare professional, such as a primary care physician or a urologist. They can provide personalized guidance based on your clinical history, lifestyle, and other established risk factors. Never use genetic data to make medical decisions or change your health habits without professional clinical advice. Genetic research is an evolving field, and while it provides valuable insights into human biology, it is not a substitute for standard medical screening and care.
How common is this variant?
The frequency of the rs2292884 variant is variable across European populations, with different allele distributions observed in various ancestral groups.
Frequently asked questions
Does the rs2292884 variant cause prostate cancer?
No, this variant does not cause prostate cancer. It is a genetic marker associated with a small, statistical difference in risk, but it is not a direct cause of the disease.
Should I get tested for rs2292884?
There is no clinical recommendation to test for this specific variant. Genetic risk scores are generally used for research purposes and do not provide actionable clinical information for individual patients.
How can I lower my risk of prostate cancer?
The best way to manage your risk is to maintain a healthy lifestyle and follow recommended screening guidelines provided by your doctor. Discuss your personal and family health history with a healthcare professional to determine the right screening plan for you.
Where can I find more information about my genetic results?
If you have received genetic testing results, consult with a certified genetic counselor or your primary care physician. They can help you interpret the information in the context of your overall health.
Sources & further reading
Educational information only, last refreshed 10/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2292884?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29